These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28121547)

  • 1. Oncology pharma costs to exceed $150 billion by 2020.
    Manag Care; 2016 Oct; 25(10):40. PubMed ID: 28121547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.
    da Veiga CRP; da Veiga CP; Drummond-Lage AP
    Crit Rev Oncol Hematol; 2018 Sep; 129():133-145. PubMed ID: 30097232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
    de Lima Lopes G; Gluck S
    J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 5. Do oncologists believe new cancer drugs offer good value?
    Nadler E; Eckert B; Neumann PJ
    Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

  • 7. Paternalism in practice: informing patients about expensive unsubsidised drugs.
    Dare T; Findlay M; Browett P; Amies K; Anderson S
    J Med Ethics; 2010 May; 36(5):260-4. PubMed ID: 20439327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The price tag on progress--chemotherapy for colorectal cancer.
    Schrag D
    N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
    [No Abstract]   [Full Text] [Related]  

  • 9. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges.
    Tartari F; Santoni M; Burattini L; Mazzanti P; Onofri A; Berardi R
    Cancer Treat Rev; 2016 Jul; 48():20-4. PubMed ID: 27310708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The costs of oncology. Results of an innovative research].
    Piccinini M; Nicolis F; Venturini M
    Tumori; 2008; 94(3):1-4. PubMed ID: 18705421
    [No Abstract]   [Full Text] [Related]  

  • 11. The high cost of cancer drugs and what we can do about it.
    Siddiqui M; Rajkumar SV
    Mayo Clin Proc; 2012 Oct; 87(10):935-43. PubMed ID: 23036669
    [No Abstract]   [Full Text] [Related]  

  • 12. New Math on Drug Cost-Effectiveness.
    Bach PB
    N Engl J Med; 2015 Nov; 373(19):1797-9. PubMed ID: 26535510
    [No Abstract]   [Full Text] [Related]  

  • 13. Shortening the infusion time of anticancer drugs: who will benefit?
    Margolin K; Gordon M
    J Clin Oncol; 2007 Jul; 25(19):2642-3. PubMed ID: 17602068
    [No Abstract]   [Full Text] [Related]  

  • 14. Skipping for herceptin funds.
    Harrison J
    Nurs N Z; 2007 Nov; 13(10):4. PubMed ID: 18084962
    [No Abstract]   [Full Text] [Related]  

  • 15. Making a case for a $2700-a-month drug.
    Sibbald B
    CMAJ; 1999 Nov; 161(9):1173. PubMed ID: 10569111
    [No Abstract]   [Full Text] [Related]  

  • 16. How much will Herceptin really cost? The money is already there.
    Minhas R
    BMJ; 2006 Dec; 333(7580):1219; discussion 1219-20. PubMed ID: 17158392
    [No Abstract]   [Full Text] [Related]  

  • 17. Biosimilars in Oncology: Reality Could Bite the Copycats, Dog Potential Major Savings.
    Kelley T
    Manag Care; 2017 Mar; 26(3):28-30. PubMed ID: 28510517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab in breast cancer.
    Mastrianni DM
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
    [No Abstract]   [Full Text] [Related]  

  • 19. How much will Herceptin really cost? Balancing local and national priorities is not new.
    Dillon A; Littlejohns P
    BMJ; 2006 Dec; 333(7580):1219; discussion 1219-20. PubMed ID: 17158393
    [No Abstract]   [Full Text] [Related]  

  • 20. Optional copayments on anti-cancer drugs.
    van de Vooren K; Curto A; Garattini L
    BMJ; 2013 Jan; 346():f349. PubMed ID: 23347986
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.